You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MRD persistent positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ph+ ALL, Bone Marrow Transplant, Minimal Residual Disease Trial in Tianjin (the usage of Olverembatinib combined with Inotuzumab

Not yet recruiting
  • Ph+ ALL
  • +2 more
  • the usage of Olverembatinib combined with Inotuzumab Ozogamicin
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital, Chinese Acade
Oct 30, 2022

MRD-tailored Therapy in Newly Diagnosed Multiple Myeloma With

Not yet recruiting
  • Multiple Myeloma
  • Minimal Residual Disease
    • (no location specified)
    Nov 1, 2023

    Acute Lymphoblastic Leukemia Trial in Hangzhou (Blinatumomab)

    Recruiting
    • Acute Lymphoblastic Leukemia
    • Hangzhou, Zhejiang, China
      The first affiliated hospital of medical college of zhejiang uni
    Nov 5, 2023

    AML, Adult, Minimal Residual Disease Trial in Guangzhou (chidamide and azacitidine)

    Not yet recruiting
    • AML, Adult
    • Minimal Residual Disease
    • chidamide and azacitidine
    • Guangzhou, Guangdong, China
      Guangdong Provincial People's Hospital
    Sep 27, 2023

    B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Trial in Tampa (Tecartus)

    Recruiting
    • B-Cell Lymphoblastic Leukemia
    • Acute Lymphoblastic Leukemia
    • Tampa, Florida
      Moffitt Cancer Center
    Nov 28, 2023

    MRD Test in Common Risk Stage II Colorectal Cancer

    Not yet recruiting
    • Stage II Colorectal Cancer
    • MRD test
    • Xi'an, Shaanxi, China
      First Affiliated Hospital of Xian Jiaotong University
    Mar 29, 2023

    Multiple Myeloma Trial in Tianjin (anti-BCMA CAR-T)

    Recruiting
    • Multiple Myeloma
    • anti-BCMA CAR-T
    • Tianjin, Tianjin, China
      Institute of Hematology and Blood Diseases Hospital Chinese Acad
    May 4, 2023

    Colorectal Cancer Trial in Shanghai, Hangzhou, Ningbo (Capecitabine tablets, Oxaliplatin)

    Not yet recruiting
    • Colorectal Cancer
    • Shanghai, Shanghai, China
    • +3 more
    Jan 16, 2023

    ALL, MRD-positive, Hematopoietic Stem Cell Transplantation Trial in Suzhou (Inotuzumab Ozogamicin)

    Recruiting
    • ALL
    • +2 more
    • Inotuzumab Ozogamicin
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Jul 14, 2023

    Multiple Myeloma Trial (Dexamethasone, Isatuximab, Lenalidomide)

    Not yet recruiting
    • Multiple Myeloma
    • (no location specified)
    Jan 10, 2023

    Acute Myeloid Leukemia, Measurable Disease Trial in Tianjin (Venetoclax, Azacitidine, Venetoclax, daunorubicin, cytarabine)

    Recruiting
    • Acute Myeloid Leukemia
    • Measurable Disease
    • Venetoclax, Azacitidine
    • Venetoclax, daunorubicin, cytarabine
    • Tianjin, Tianjin, China
      HBDH
    Apr 28, 2022

    AML, MDS Trial in Houston (Vibecotamab, Dexamethasone, Acetaminophen)

    Recruiting
    • AML
    • MDS
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 29, 2022

    Significance of MRD After Surgery in Driver Gene-positive and

    Enrolling by invitation
    • NSCLC MRD ctDNA
      • Shenzhen, China
        ShenzhenPH
      Jun 30, 2022

      Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD) Trial in Baltimore (BLINCYTO (Blinatumomab))

      Recruiting
      • Mixed Phenotype Acute Leukemia (MPAL)
      • Measurable Residual Disease (MRD)
      • BLINCYTO (Blinatumomab)
      • Baltimore, Maryland
        Greenebaum Cancer Center at University of Maryland Medical Cente
      Apr 18, 2022

      Acute Myeloid Leukemia, Adult Trial in Germany (Midostaurin)

      Terminated
      • Acute Myeloid Leukemia, Adult
      • Chemnitz, Germany
      • +3 more
      Jan 20, 2022

      Colorectal Cancer Trial (mFOLFOXIRI, mFOLFOX6)

      Not yet recruiting
      • Colorectal Cancer
      • (no location specified)
      Jun 17, 2022

      HER2-positive Breast Cancer Trial in Chuo-ku

      Recruiting
      • HER2-positive Breast Cancer
        • Chuo-ku, Tokyo, Japan
          National Cancer Center Hospital, Japan
        Jun 22, 2022

        Breast Cancer Trial (Giredestrant, Abemaciclib, Inavolisib)

        Not yet recruiting
        • Breast Cancer
        • (no location specified)
        Feb 1, 2023

        Prophylactic HQP1351 Therapy, Third Generation TKI Trial in Guanzhou (HQP1351( Olverembatinib dimesylate))

        Withdrawn
        • Prophylactic HQP1351 Therapy
        • Third Generation TKI
        • HQP1351( Olverembatinib dimesylate)
        • Guanzhou, China
          Department of Hematology, Nanfang Hospital, Southern Medical Uni
        Jan 16, 2023

        Colon Cancer Trial (mFOLFIRINOX-FOLFIRI intensified chemo, FOLFOX or CAPOX adjuvant chemo)

        Not yet recruiting
        • Colon Cancer
        • mFOLFIRINOX-FOLFIRI intensified chemotherapy
        • FOLFOX or CAPOX adjuvant chemotherapy
        • (no location specified)
        Sep 6, 2022

        B-ALL Trial in Hangzhou (ThisCART19A)

        Recruiting
        • B-ALL
        • ThisCART19A
        • Hangzhou, Zhejiang, China
          The first affiliated hospital of medical college of zhejiang uni
        Apr 26, 2022

        HPV, Oropharyngeal Cancer Trial in Houston (Balstilimab)

        Not yet recruiting
        • HPV
        • Oropharyngeal Cancer
        • Houston, Texas
          M D Anderson Cancer Center
        Dec 5, 2022

        Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)

        Not yet recruiting
        • Cervical Cancer
        • Recombinant humanized anti-PD-1 monoclonal antibody injection
        • +4 more
        • Wuhan, Hubei, China
          Tongji Hospital affiliated to Tongji Medical College of Huazhong
        Nov 3, 2023

        Core Binding Factor Acute Myeloid Leukemia, KIT Mutation-Related Tumors Trial in Suzhou (Avapritinib)

        Recruiting
        • Core Binding Factor Acute Myeloid Leukemia
        • KIT Mutation-Related Tumors
        • Suzhou, Jiangsu, China
          First Affiliated Hospital of Soochow University
        Apr 7, 2023

        Adenocarcinoma of Lung Trial in Beijing (Furmonertinib)

        Not yet recruiting
        • Adenocarcinoma of Lung
        • Beijing, China
          Peking University People's Hospital
        Oct 3, 2021